BiotechTube

DNK333

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Apr 1, 2004 → Sep 1, 2005

NCT ID
NCT00699166

About DNK333

DNK333 is a phase 2 stage product being developed by Novartis for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00699166. Target conditions include Irritable Bowel Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00699166Phase 2Completed

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
SMS995 + PlaceboNovartisPhase 1
29
DNK333 + PlaceboNovartisPhase 2
35